mva-bn-hiv
Vaccineexperimental
Clinical trial activity
2 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2021 (NCT04983030)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05769569 | Phase 1 | Sep 1, 2023 | Chulalongkorn University, Henry M. Jackson Foundation for the Advancement of Military Medicine, Janssen Pharmaceutica NV, United States Army |
| NCT04983030 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2021 | Harvard University, Janssen Pharmaceutica NV, National Institute of Allergy and Infectious Diseases (NIAID), Orlando Immunology Center, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 2 | 0 | 2 | 2021 |
| Chulalongkorn University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 1 | 1 | 1 | 2023 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2021 |
| Orlando Immunology Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
| United States Army | Government | 1 | 0 | 1 | 2023 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2021 |
8 organizations
Page 1 / 1